Ravidasvir

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ravidasvir
Accession Number
DB15652
Description

Ravidasvir is under investigation in clinical trial NCT02961426 (Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 762.912
Monoisotopic: 762.385331362
Chemical Formula
C42H50N8O6
Synonyms
  • Ravidasvir
External IDs
  • BI 238630
  • BI-238630
  • BL-238630
  • PPI-668 free base

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Ravidasvir hydrochlorideHWN73766811303533-81-4JYLMWUZJMRNMDA-SPRBZRACSA-N

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
AL3G001BI8
CAS number
1242087-93-9
InChI Key
LCHMHYPWGWYXEL-ZYADHFCISA-N
InChI
InChI=1S/C42H50N8O6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54)/t33-,34-,35-,36-/m0/s1
IUPAC Name
methyl N-[(2S)-1-[(2S)-2-[4-(6-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-1,3-benzodiazol-5-yl}naphthalen-2-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
SMILES
COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)C=C(C=C2)C1=CC2=C(NC(=N2)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1

References

General References
Not Available
ChemSpider
31141686
ChEMBL
CHEMBL3121849
Wikipedia
Ravidasvir

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection2
2, 3Active Not RecruitingTreatmentChronic Hepatitis C Virus (HCV) Infection1
2, 3CompletedTreatmentHepatitis C Virus (HCV) Infection1
2, 3RecruitingTreatmentHepatitis C Viral Infection1
1CompletedNot AvailablePharmacokinetic Assessments in Healthy Volunteers1
1CompletedBasic SciencePharmacokinetic Assessments in Healthy Volunteers2
1CompletedTreatmentBioequivalence Study1
1CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection2
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers / Hepatitis C Virus (HCV) Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00444 mg/mLALOGPS
logP5.4ALOGPS
logP5.47ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)11.34ChemAxon
pKa (Strongest Basic)5.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area174.64 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity208.96 m3·mol-1ChemAxon
Polarizability84.79 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on March 31, 2020 15:52 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates